Navigation Links
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
Date:5/13/2008

, heart attack and other conditions

associated with increased platelet aggregation.

-- Received notification that an abstract describing the results from the

completed Phase IIb clinical trial of tezampanel for the treatment of

acute migraine was accepted for presentation at the 50th Annual

Scientific Meeting of the American Headache Society to be held in

Boston June 26-29, 2008.

Financial Results

Revenue for the three month period ended March 31, 2008, was $2.0 million, compared to revenue of $2.5 million for the same period in 2007. Operating expenses for the quarter ended March 31, 2008, were $6.7 million, with $5.3 million attributable to research and development. This compares to operating expenses of $6.6 million and research and development expenses of $5.2 million for the same period last year. The company reported a net loss for the quarter ended March 31, 2008, of $3.9 million compared to a net loss of $3.3 million for the previous year.

Conference Call/Webcast Information

TorreyPines will host a conference call and Webcast at 11 a.m. EDT today. The audio Webcast can be accessed at http://www.torreypinestherapeutics.com. To participate in this call, dial 719-325-4817 and enter the passcode 2644321. For a limited period following the call, a replay will be available beginning at 2 p.m. EDT. The replay can be accessed by calling 719-457-0820 and entering passcode 2644321.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
2. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
3. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
11. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... The excitement is building up once again for the annual ... year the Surry Arts Council will be celebrating its 25th year ... are still fans of the Andy Griffith Show. ... CBS from 1960 through 1968. The show ranked by TV ... Mount Airy, North Carolina is where the show was filmed calling ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 2014 Final Cut Pro X Plugin ... of the Information theme for FCPX filmmakers. , “Fun, cool, ... the Information theme,” says Christina Austin, CEO of Pixel Film ... professional.” , Information features easy to use controls that give ... environment. Change the background color, color of each circle outline, ...
(Date:9/20/2014)... 20, 2014 MarijuanaDoctors.com recently returned ... at the PAIN Week conference that was held ... Casino in Las Vegas from September 2nd to ... PAIN Week in the hopes of educating physicians ... and legitimate tool to treat chronic Pain, MarijuanaDoctors.com ...
(Date:9/19/2014)... September 19, 2014 “Copay coupons,” a ... of brand drugs among patients with prescription drug coverage, ... to a new report from the Department of ... (OIG). Federal anti-kickback laws prohibit suppliers from offering side-payments ... the federal government. , The report highlights that two ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... well-proven medications, could have huge impact, expert says , ... of a statin and a blood pressure-lowering ACE inhibitor ... or stroke reduced their incidence by more than 60 ... the study all had diabetes or a history of ...
... BNVI ) today announced that it has entered into agreements ... price per unit of $6.20 for aggregate gross proceeds of up ... common stock and ten warrants. Each warrant entitles its holder ... price of $0.85. The warrants may be exercised at any ...
... Anterior cruciate ligament (ACL) injuries are one of the ... of patients undergo reconstructive surgery to repair these injuries. ... issue of The Journal of Bone and Joint Surgery ... increasing substantially and women and younger patients are more likely ...
... have demonstrated that a protein called NEDD9 may be required ... to grow. Their findings, based on the study of a ... issue of Cancer Research , available on-line now. ... evidence that directly demonstrates reduced levels of NEDD9 in a ...
... No clear evidence found that Chantix has dangerous side ... News) -- The smoking cessation drug varenicline (Chantix) does ... to a new British study. , In July, the ... carry a "black-box warning" on its packaging, indicating that ...
... iMobile® Care ... ... information to provide essential and practical aid and care during serious situations is crucial and ... able to deliver a timely response, or to administer self-care without a costly physician or ...
Cached Medicine News:Health News:Drug Combo May Prevent Heart Attacks, Strokes 2Health News:Drug Combo May Prevent Heart Attacks, Strokes 3Health News:Bionovo Announces Pricing of Securities Offering 2Health News:Bionovo Announces Pricing of Securities Offering 3Health News:Teenagers and ACL: Tears common and additional surgery likely 2Health News:NEDD9 protein supports growth of aggressive breast cancer 2Health News:Study Counters Warnings on Quit-Smoking Drug 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 2Health News:VisionSync Launches a Smart iPhone First Aid App, iMobile Care 3
(Date:9/19/2014)... 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... marketed as XIAFLEX ® in the U.S. and XIAPEX ... Tom Wegman , will present a corporate overview at ... Industry Conference. The presentation will take place ... the Millennium Broadway Hotel in New York, NY ...
(Date:9/19/2014)... Tenn. , Sept. 19, 2014  Over 200 ... the Future to Benefit the Radiation Oncology Institute (ROI), ... held at Golden Gate Park in San Francisco.  ... Dan Moore , CEO of Radiation Business Solutions, ... we have raised over $70,000 for the ROI this ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... 17, 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the ... clinical trial of the triplet combination of ... the,first-line treatment of advanced non-small cell lung ... significant,improvement in both progression-free survival and overall ...
... Antiproliferative and Antiangiogenic Activity Demonstrated in,Preclinical ... Md., April 17, 2007 /PRNewswire-FirstCall/ --,EntreMed, ... developing,therapeutics for the treatment of cancer ... of preclinical data for its,clinical-stage product ...
Cached Medicine Technology:Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 2EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 3EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR,Annual Meeting 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: